Octave Specialty (OSG) Current Deferred Revenue (2010 - 2026)

Octave Specialty's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $198.7 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 9.53% year-over-year to $198.7 million; the TTM figure through Mar 2026 stood at $198.7 million (up 9.53% YoY), while the FY2025 annual figure was $187.2 million, up 2.59% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $198.7 million, up from $187.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $458.0 million in Q3 2024, with the low at $85.4 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $359.0 million (2022), against an average of $296.3 million.
• The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue surged 754.15% in 2022, then tumbled 57.72% in 2025.
• Octave Specialty's Current Deferred Revenue stood at $85.4 million in 2022, then surged by 81.32% to $154.9 million in 2023, then gained by 17.8% to $182.4 million in 2024, then advanced by 2.59% to $187.2 million in 2025, then climbed by 6.15% to $198.7 million in 2026.
• Business Quant data shows OSG's Current Deferred Revenue at $198.7 million in Q1 2026, $187.2 million in Q4 2025, and $197.1 million in Q3 2025.